ALPMF - Astellas Pharma Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Astellas Pharma Inc.

2-5-1, Nihonbashi-Honcho
Chuo
Tokyo 103-8411
Japan
81 3 3244 3000
http://www.astellas.com

Sector
Industry
Full Time Employees17,202

Key Executives

NameTitlePayExercisedAge
Mr. Yoshihiko HatanakaPres, CEO & Representative Director1.69MN/AN/A
Mr. Chikashi TakedaChief Financial OfficerN/AN/AN/A
Mr. Percival Barretto-KoSr. VP of International OperationsN/AN/AN/A
Mr. Fumiaki SakuraiChief Admin. Officer & Chief Ethics & Compliance OfficerN/AN/AN/A
Ms. Linda Friedman J.D.Gen. Counsel & VPN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Astellas Pharma Inc., a pharmaceutical company, manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, an immunosuppressant used to suppress organ transplant rejection; Vesicare, a treatment for overactive bladder; Harnal/Omnic, a blocking agent to treat the functional symptoms of benign prostatic hyperplasia; and Funguard/MYCAMIN, a candin-type antifungal agent. It also provides Geninax, an oral new-type quinolone antibacterial agent; Celecox, an anti-inflammatory agent; Lipitor, a treatment for hypercholesterolemia; Micardis/Micombi/Micamlo, a treatment for hypertension; Gaster, a treatment for peptic ulcer and gastritis; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic agonist indicated for the treatment of overactive bladder; Eligard, a luteinizing hormone-releasing hormone agonist for the treatment of prostate cancer; XTANDI for the treatment of prostate cancer; and VESOMNI, a release tablet for the treatment of moderate to severe storage symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not adequately responding to treatment with monotherapy. In addition, the company offers Symbicort for the treatment for adult bronchial asthma and chronic obstructive pulmonary disease; Bonoteo for the treatment for osteoporosis; Suglat for the treatment of type 2 diabetes; and Repatha for the treatment of hypercholesterolemia. Further, the company provides Lexiscan, a pharmacologic stress agent; Tarceva, a treatment for non-small cell lung cancer; CRESEMBA, a azole antifungal; and Dificlir, a novel treatment for CDI. Additionally, it is developing enzalutamide, gilteritinib, and degarelix for oncology indications. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

Corporate Governance

Astellas Pharma Inc.’s ISS Governance QualityScore as of October 15, 2017 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 2; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.